Other Events ·
Radiopharm Theranostics announced that positive interim data from its Phase 2b imaging trial of RAD101 was selected…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics announced that positive interim data from its Phase 2b imaging trial of RAD101 was selected for a late-breaking oral presentation at the Society of Neuro-Oncology Annual Meeting. The data demonstrated 93% concordance between RAD101 PET and MRI across all evaluable lesions, meeting the primary endpoint. Additionally, preliminary sensitivity was 86% based on six-month follow-up or biopsy data in 14 patients. The company plans to meet with the FDA on October 1, 2026, to align on a Phase 3 pivotal trial protocol and has partnered with Siemens Healthineers for manufacturing and distribution support. Radiopharm Theranostics operates in the biotechnology industry, developing radiopharmaceuticals for oncology diagnostics and therapeutics.